Brief: Clarity Pharmaceuticals Says Additional COBRA Results For SAR-bisPSMA Detects Lesions In 2-millimetre Range
08/03/2024 14:28
March 8 (Reuters) - Clarity Pharmaceuticals Ltd
CU6.AX :
* CLARITY PHARMACEUTICALS LTD: ADDITIONAL COBRA RESULTS FOR
SAR-BISPSMA DETECTS LESIONS IN 2-MILLIMETRE RANGE
Source text for Eikon: ID:nPn8BMZn5a
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial